Menon Announces Advancement of Trials on Rapid COVID-19 Test at the University of California San Diego
Excerpt from the Press Release:
SAN DIEGO, Jan. 19, 2021 /PRNewswire/ — Menon Biosensors, Inc. (“Menon” or the “Company”), a distributive technology portfolio company, announced today that trials will advance on its proprietary Molecular Mirror™ platform technology in collaboration with the University of California San Diego School of Medicine (“UC San Diego”) hoping to prove accuracy and feasibility as a rapid assay for detection of SARS-CoV-2 (“COVID-19”) virus in patient specimens.
The advancement comes after scientists at UC San Diego’s Clinical Molecular Microbiology Laboratory, led by David Pride, MD PhD, and Menon successfully completed on-site preliminary trials on over 200 samples. The trials showed that combining Molecular Mirror™ technology with a standard magnetic resonance imaging (“MRI”) machine or benchtop magnetic resonance instrument could create a rapid output testing process for detection of the COVID-19 virus, which would be capable of testing upward of 100,000 samples per hour if proven and deployed.
Click the button below to read the entire Press Release:
Discover What Sets TrialStat Apart From Ordinary Data Management
Click the image or button below to explore our interactive infographic which illustrates the comprehensive and unique capabilities of the TrialStat eClinical Suite.
Request Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?